North America Smart Inhalers Market Analysis and Opportunities by 2027

The North America smart inhalers market is expected to reach US$ 3,749.90 Mn in 2027 from US$ 503.91 Mn in 2018. The market is estimated to grow with a CAGR of 25.7% from 2019-2027.

The growth of the market is driven by the factors such as, growing geriatric population rising prevalence of COPD and asthma, along with rising awareness regarding the medical condition. However, the market is likely to get impacted due to risks associated with cyber threats limited knowledge regarding the use of smart inhalers.

The cases of asthma and COPD has been increasing across the globe at a significant rate. During recent years, there has been rise in the number of smokers as well as air pollution in developed as well as developing countries. Asthma is a non-communicable disease categorized by recurrent attacks of breathlessness and wheezing, which differ in severity and frequency from person to person. While an asthma attack occurs, the lining of the bronchial tubes swells, affecting the airways to narrow, hence limiting the flow of air into and out of the lungs. Recurrent asthma symptoms frequently lead to feeling of daytime fatigue, sleeplessness, reduced activity levels and school and work absence. As per estimates provided by the WHO, there are currently 235 million people suffering from asthma across the globe. As per the Centers for Disease Control and Prevention (CDC), the number of adults above 18 years of age currently having asthma are approximately 19 million in the United States, accounting for almost 7.7% of the total adult population.

Similarly, there has been rising prevalence of COPD across the North America. Chronic obstructive pulmonary disease (COPD) is a progressive fatal lung disease that leads to breathlessness, leading to predisposes then exacerbations and later causes serious illness. As per the Global Burden of Disease Study report, a prevalence of around 251 million cases of COPD were recorded globally during the year 2016. It is estimated that globally approximately 3.17 million deaths were caused due to COPD during the year 2015, accounting for almost 5% of all deaths in 2015. The prevalence of COPD has been high in developed nations during the recent years. For instance, COPD is recognized as the third leading cause of death by disease in the United States. Approximately, 11 million individual are diagnosed with COPD. Hence, the rising prevalence of respiratory conditions such as asthma and COPD is anticipated to fuel the growth of the smart inhalers market across the globe at an exponential rate.

US is expected to lead the market in the North America region because the US has presence of various associations which provide help in the field of lung diseases. For instance, American Lung Association conducts research activities, education and training as well as undertakes initiatives to offer better treatment and support for the patients suffering with respiratory conditions such as asthma, COPD, influenza, lung cancer, pneumonia, and pulmonary fibrosis among others. Therefore, considering the above mentioned factors the growth of the market in the country is likely to contribute largest share in the North America region during the forecast period.

NORTH AMERICA SMART INHALERS – MARKET SEGMENTATION

By Product

• Inhalers
• Nebulizers

By Disorder

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)

By End User

• Home-care Settings
• Hospitals & Clinics

By Geography

• North America
  • US
  • Canada
  • Mexico

Company Profiles

• GlaxoSmithKline plc
• Adherium Ltd.
• Vectura Group plc
• Novartis AG
• Findair Sp. z o. o.
• Cohero Health
• Crux Product Design Ltd
• Teva Pharmaceuticals
• 3M
• Amiko Digital Health Limited

North America Smart Inhalers Report Scope